Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – A post-hoc analysis of the PRIORITY randomized clinical trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – A post-hoc analysis of the PRIORITY randomized clinical trial. / on the behalf of the PRIORITY Study Group.
In: Journal of Diabetes and its Complications, Vol. 37, No. 4, 108433, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – A post-hoc analysis of the PRIORITY randomized clinical trial
AU - Rotbain Curovic, Viktor
AU - Tofte, Nete
AU - Lindhardt, Morten
AU - Adamova, Katarina
AU - Bakker, Stephan J.L.
AU - Beige, Joachim
AU - Beulens, Joline W.J.
AU - Birkenfeld, Andreas L.
AU - Currie, Gemma
AU - Delles, Christian
AU - Dimos, Ingo
AU - Francová, Lidmila
AU - Frimodt-Møller, Marie
AU - Girman, Peter
AU - Göke, Rüdiger
AU - Hansen, Tine W.
AU - Havrdova, Tereza
AU - Kooy, Adriaan
AU - Laverman, Gozewijnw D.
AU - Mischak, Harald
AU - Navis, Gerjan
AU - Nijpels, Giel
AU - Noutsou, Marina
AU - Ortiz, Alberto
AU - Parvanova, Aneliya
AU - Persson, Frederik
AU - Petrie, John R.
AU - Ruggenenti, Piero L.
AU - Rutters, Femke
AU - Rychlík, Ivan
AU - Siwy, Justyna
AU - Spasovski, Goce
AU - Speeckaert, Marijn
AU - Trillini, Matias
AU - Zürbig, Petra
AU - von der Leyen, Heiko
AU - Rossing, Peter
AU - on the behalf of the PRIORITY Study Group
N1 - Publisher Copyright: © 2023 Elsevier Inc.
PY - 2023
Y1 - 2023
N2 - Aims: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes. Methods: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m2); and CVE. Models were adjusted for relevant risk factors. Results: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR. Conclusions: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.
AB - Aims: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes. Methods: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m2); and CVE. Models were adjusted for relevant risk factors. Results: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR. Conclusions: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.
KW - Albuminuria
KW - Cardiovascular disease
KW - Chronic kidney disease
KW - Diabetic retinopathy
KW - Risk stratification
KW - Type 2 diabetes
U2 - 10.1016/j.jdiacomp.2023.108433
DO - 10.1016/j.jdiacomp.2023.108433
M3 - Journal article
C2 - 36841085
AN - SCOPUS:85148723564
VL - 37
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
SN - 1056-8727
IS - 4
M1 - 108433
ER -
ID: 369351809